ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+24.05%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$59.8M
AUM Growth
+$59.8M
(+65%)
Cap. Flow
+$14.1M
Cap. Flow
% of AUM
23.6%
Top 10 Holdings %
Top 10 Hldgs %
72.36%
Holding
33
New
10
Increased
12
Reduced
3
Closed
8
Top Buys
| 1 |
Gilead Sciences
GILD
|
$4.54M |
| 2 |
Inogen
INGN
|
$4.15M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$3.25M |
| 4 |
Illumina
ILMN
|
$2.58M |
| 5 |
Centene
CNC
|
$2.28M |
Top Sells
| 1 |
Insmed
INSM
|
$6.35M |
| 2 |
Incyte
INCY
|
$2.01M |
| 3 |
Neurocrine Biosciences
NBIX
|
$1.47M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$1.11M |
| 5 |
DaVita
DVA
|
$1.09M |
Sector Composition
| 1 | Healthcare | 82.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
1
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.38M | 10.66% | 183,902 +13,773 | +8% | +$478K |
|
2
PTC Therapeutics
PTCT
$3.92B
| $5.75M | 9.61% | 152,828 +42,034 | +38% | +$1.58M |
|
|
3
Inogen
INGN
$216M
| $5.11M | 8.54% | 53,575 +43,503 | +432% | +$4.15M |
|
|
4
Gilead Sciences
GILD
$140B
| $4.54M | 7.59% | +69,879 | New | +$4.54M |
|
|
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.53M | 7.58% | 85,661 -21,023 | -20% | -$1.11M |
|
|
6
Insmed
INSM
$28.8B
| $4.5M | 7.52% | 154,887 -218,311 | -58% | -$6.35M |
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $3.41M | 5.69% | 71,675 +14,189 | +25% | +$674K |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $3.25M | 5.44% | +62,561 | New | +$3.25M |
|
|
9
Centene
CNC
$14.3B
| $3.14M | 5.24% | 59,093 +42,904 | +265% | +$2.28M |
|
10
UnitedHealth
UNH
$281B
| $2.69M | 4.49% | 10,864 +3,980 | +58% | +$984K |
|
|
11
Illumina
ILMN
$15.8B
| $2.58M | 4.32% | +8,318 | New | +$2.58M |
|
|
CBIO
12
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $1.71M | 2.85% | +136,990 | New | +$1.71M |
|
13
Heron Therapeutics
HRTX
$207M
| $1.66M | 2.77% | 67,909 +37,048 | +120% | +$906K |
|
14
Penumbra
PEN
$10.6B
| $1.65M | 2.76% | 11,254 +1,288 | +13% | +$189K |
|
|
XLRN
15
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.4M | 2.34% | 30,125 +11,561 | +62% | +$538K |
|
16
CVS Health
CVS
$92.8B
| $1.02M | 1.71% | 28,680 +6,941 | +32% | +$248K |
|
17
Alkermes
ALKS
$4.78B
| $1.01M | 1.69% | +27,673 | New | +$1.01M |
|
18
iRhythm Technologies
IRTC
$5.46B
| $823K | 1.38% | +10,978 | New | +$823K |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $818K | 1.37% | +8,754 | New | +$818K |
|
|
NCNA
20
NuCana
NCNA
$6.09M
| $772K | 1.29% | 45,393 +2,346 | +5% | +$39.9K |
|
21
Verrica Pharmaceuticals
VRCA
$52.8M
| $762K | 1.27% | 70,458 +7,576 | +12% | +$81.9K |
|
22
Natera
NTRA
$23.1B
| $628K | 1.05% | +30,458 | New | +$628K |
|
|
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
| $618K | 1.03% | 83,611 -13,353 | -14% | -$98.7K |
|
24
Twist Bioscience
TWST
$1.63B
| $550K | 0.92% | +23,733 | New | +$550K |
|
25
Pacira BioSciences
PCRX
$1.2B
| $528K | 0.88% | +13,881 | New | +$528K |
|